Benefits of immunotherapy, cancer-targeted treatment in triple combo drug for melanoma
A groundbreaking new triple combination therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor + immunotherapy combos alone, and with increased immune response and fewer side effects. Read More
